Legal, Patents, pharma law, plausibility
0 Comment
Pharma needs clarity from the Supreme Court on whether the whole scope of a patent claim must be plausible at the time of the application.
patient access, patient centricity
0 Comment
Now is the time to work more harmoniously together to improve patient access to innovative treatments.
EU drug pricing, EU market access, Health Technology Assessment, HTA, market access
0 Comment
business flexibility, business model, virtual business model
0 Comment
pharma supply chain, supply chain management
0 Comment
In the pharma industry, companies need to know where products are at any point in the supply chain, but with one of the most complex systems of any industry, what are the pressure points and how can they be managed?
affordable drugs, Deep Dive, patient centricity, patients, US drug market, US drug prices
0 Comment
In the latest edition of our Deep Dive magazine – Deep Dive: Patient Centricity II – David Mitchell, President of Patients For Affordable Drugs, speaks to pharmaphorum’s Andrew McConaghie about why the organisation was set up and why its campaigning work is so important for patients.
Brexit, market access, pharma market access, UK drug market, UK pharma market access
0 Comment
A UK market access summit convened by IQVIA brought together pharma and NHS leaders to look at how working more closely – including more outcomes-based deals – could help UK life sciences through Brexit and beyond.
DMD, Duchenne, Duchenne muscular dystrophy, LHON, patient centricity
0 Comment
Santhera is putting patient needs at the heart of its rare disease speciality business. Chief Executive Officer Thomas Meier, PhD, talks about the company’s mission – and how rationalising Europe’s drug review systems could help patients.
